# Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00438204** · PHASE2 · TERMINATED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 39 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** pemetrexed disodium

## Key facts

- **NCT ID:** NCT00438204
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2013-03
- **Final completion:** 2016-06
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** All data collection has completed.
- **Last updated:** 2021-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00438204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00438204, "Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00438204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*